Zhao-xia Liu

发表

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, Journal for ImmunoTherapy of Cancer.

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

Le Xu, Yuan Chang, Baoying Hu, 2021, Cancer Immunology, Immunotherapy.

Poor clinical outcomes and immunoevasive contexture in interleukin‐9 abundant muscle‐invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, International journal of cancer.

Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Variation in contents of major bioactive compounds in Glechoma longituba related to harvesting time and geographic distribution

Q. Guo, Zaibiao Zhu, Li Liu, 2012 .

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

Y. Zhu, Le Xu, Weijuan Zhang, 2022, British Journal of Cancer.

Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Hongyi Zhang, 2022, Cancer Immunology, Immunotherapy.

B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.

Le Xu, Jiejie Xu, Yu Zhu, 2022, European journal of cancer.

Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.

Le Xu, Yuan Chang, Baoying Hu, 2022, Urologic oncology.

Tumor-infiltrating TNFRSF9+ CD8+ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response

Le Xu, Yuan Chang, Jiejie Xu, 2020, Oncoimmunology.

Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5+ CD8+ T cell abundance

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Le Xu, Yuan Chang, Jiejie Xu, 2021, Journal for ImmunoTherapy of Cancer.

Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for immunotherapy of cancer.

Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis

Le Xu, Yuan Chang, Jiejie Xu, 2021, Cancer Immunology, Immunotherapy.

Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, Journal for ImmunoTherapy of Cancer.

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Li Liu, 2022, British Journal of Cancer.

Tumor-infiltrating IL-17A+ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, Oncoimmunology.

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

Le Xu, Jiejie Xu, Shengming Jin, 2022, Annals of Surgical Oncology.

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients

B. Dai, Le Xu, Hongyu Zhang, 2020, Journal for ImmunoTherapy of Cancer.

Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients.

Le Xu, Yuan Chang, Jiejie Xu, 2021, Urologic oncology.

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer

B. Dai, Le Xu, Hongyu Zhang, 2020, Cancer Immunology, Immunotherapy.

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, British Journal of Cancer.

Smoking And Early-Onset Basal Cell Carcinoma

L. Ferrucci, Zhao-xia Liu, 2022 .

Holotransferrin enhances selective anticancer activity of artemisinin against human hepatocellular carcinoma cells

Jian-jun Zhang, Li Liu, Zhao-xia Liu, 2013, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.

Y. Zhu, Le Xu, Jiejie Xu, 2023, Urologic oncology.

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome geneKDM6Amutation

Le Xu, Jiejie Xu, Yu Zhu, 2023, BMJ Oncology.

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Yu Zhu, 2024, British journal of cancer.

RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.

Yu Zhu, Weijuan Zhang, Zewei Wang, 2024, Journal of immunotherapy.

Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

Le Xu, Yu Zhu, Weijuan Zhang, 2024, Cancer science.

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma

Le Xu, Jiejie Xu, Yu Zhu, 2024, The Journal of pathology.

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Le Xu, Jiejie Xu, Yu Zhu, 2024, Cancer medicine.

Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Weijuan Zhang, Zewei Wang, 2023, BMC Cancer.